<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14</volume><submitter>Pearce HA</submitter><funding>National Heart Foundation of Australia</funding><funding>Victorian Government’s Operational Infrastructure Support Program</funding><funding>National Health and Medical Research Council</funding><funding>Australian Research Council</funding><pubmed_abstract>Gene therapy holds great potential for conditions such as cardiovascular disease, including atherosclerosis and also vascular cancers, yet available vectors such as the adeno-associated virus (rAAV) transduce the vasculature poorly. To enable retargeting, a single-chain antibody (scFv) that binds to the vascular cell-adhesion molecule (VCAM-1) overexpressed at areas of endothelial inflammation was site specifically and covalently conjugated to the exterior of rAAV6. To achieve conjugation, the scFv was functionalized with an orthogonal click chemistry group. This conjugation utilized site-specific sortase A methodology, thus preserving scFv binding capacity to VCAM-1. The AAV6 was separately functionalized with 4-azidophenyl glyoxal (APGO) via covalent adducts to arginine residues in the c</pubmed_abstract><journal>Molecular therapy. Methods &amp; clinical development</journal><pagination>261-269</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6704353</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Site-Specific Glycation and Chemo-enzymatic Antibody Sortagging for the Retargeting of rAAV6 to Inflamed Endothelium.</pubmed_title><pmcid>PMC6704353</pmcid><pubmed_authors>Qian H</pubmed_authors><pubmed_authors>Huang D</pubmed_authors><pubmed_authors>Hagemeyer CE</pubmed_authors><pubmed_authors>Connell TU</pubmed_authors><pubmed_authors>Peter K</pubmed_authors><pubmed_authors>Gregorevic P</pubmed_authors><pubmed_authors>Gottstein C</pubmed_authors><pubmed_authors>Pearce HA</pubmed_authors><pubmed_authors>Donnelly PS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Site-Specific Glycation and Chemo-enzymatic Antibody Sortagging for the Retargeting of rAAV6 to Inflamed Endothelium.</name><description>Gene therapy holds great potential for conditions such as cardiovascular disease, including atherosclerosis and also vascular cancers, yet available vectors such as the adeno-associated virus (rAAV) transduce the vasculature poorly. To enable retargeting, a single-chain antibody (scFv) that binds to the vascular cell-adhesion molecule (VCAM-1) overexpressed at areas of endothelial inflammation was site specifically and covalently conjugated to the exterior of rAAV6. To achieve conjugation, the scFv was functionalized with an orthogonal click chemistry group. This conjugation utilized site-specific sortase A methodology, thus preserving scFv binding capacity to VCAM-1. The AAV6 was separately functionalized with 4-azidophenyl glyoxal (APGO) via covalent adducts to arginine residues in the c</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Sep</publication><modification>2025-04-04T14:27:31.003Z</modification><creation>2019-08-31T07:06:59Z</creation></dates><accession>S-EPMC6704353</accession><cross_references><pubmed>31453264</pubmed><doi>10.1016/j.omtm.2019.07.003</doi></cross_references></HashMap>